Polyamine enhanced formulations for triptan compound iontophoresis

A technology of iontophoresis and compounds, applied in electrotherapy, active ingredients of heterocyclic compounds, medical preparations of non-active ingredients, etc., can solve problems such as pollution, expensive programmable controllers, damage, etc.

Inactive Publication Date: 2011-05-18
TEVA PHARMACEUTICALS INTERNATIONAL GMBH
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A notable limitation of the device is the two-component construction of the delivery system; the wire connection between the controller and the patch is cumbersome to the wearer
Further...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polyamine enhanced formulations for triptan compound iontophoresis
  • Polyamine enhanced formulations for triptan compound iontophoresis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] Example 1: Use of an iontophoretic patch for the delivery of sumatriptan succinate

[0096] A single-center, open label, single-dose, five-period study was conducted to compare the pharmacokinetics and Comparison of 100 mg oral sumatriptan succinate. Subjects were required to participate in Treatment A and Treatment B at a minimum.

[0097] The iontophoretic patch used has its own external power source and is designed to be applied to the surface of the skin and deliver the drug systemically.

[0098] The patch treatments and the prototype iontophoretic patches prepared for this example are detailed in Table 2 below.

[0099] Table 2 Patch quantitative treatment of iontophoresis

[0100]

[0101] Nine subjects participated in Treatment B, 100 mg sumatriptan succinate oral tablet. The study consisted of a screening visit after treatments A, B, C, D and E. Each treatment period was separated by a 2-day rest period.

[0102] The patches for Treatments A and C we...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A patch and compositions for iontophoresis of triptan compounds are described.

Description

technical field [0001] This application claims priority to US Application Serial No. 12 / 214,555, filed June 19, 2008, which is hereby incorporated by reference in its entirety. Background technique [0002] The method of iontophoresis was described by LeDuc in 1908 and has thus found commercial use in the delivery of ionically charged therapeutic molecules such as pilocarpine, lidocaine and dexamethasone. In this delivery method, positively charged ions are driven through the skin at the anode of the electrolytic system while negatively charged ions are driven through the skin at the cathode of the electrolysis system. [0003] Early, and current, devices for iontophoresis typically consist of two electrodes affixed to the patient by an adhesive material, each connected by wires to a remote power source, usually a microprocessor-controlled electrical instrument. [0004] A recent publication showed that sumatriptan can be efficiently transported transdermally using iontopho...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61F13/00A61K9/70A61K31/40
CPCA61K9/7023A61K9/0009A61N1/30A61K31/4045A61P25/06A61K47/12A61K47/32A61K47/34A61N1/303
Inventor T·B·塞布里M·霍斯特曼M·萨米提
Owner TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap